Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
23.22
-0.46 (-1.94%)
May 29, 2026, 4:00 PM EDT - Market closed
Pacira BioSciences Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Pacira BioSciences stock has a consensus rating of "Buy" and an average price target of $29.29. The average 1-year stock price forecast is 26.14% higher than the current stock price, while the lowest is $23 (-0.95%) and the highest is $38 (+63.65%).
Price Target: $29.29 (+26.14%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Pacira BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold Maintains $25 | Hold | Maintains | $25 | +7.67% | May 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $38 | Buy | Reiterates | $38 | +63.65% | May 4, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 1, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $22 → $24 | Hold | Maintains | $22 → $24 | +3.36% | May 1, 2026 |
| Needham | Needham | Buy Maintains $30 → $32 | Buy | Maintains | $30 → $32 | +37.81% | May 1, 2026 |
Financial Forecast
Revenue This Year
780.44M
from 726.41M
Increased by 7.44%
Revenue Next Year
841.73M
from 780.44M
Increased by 7.85%
EPS This Year
2.93
from 0.16
Increased by 1,753.45%
EPS Next Year
3.67
from 2.93
Increased by 25.46%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 807.5M | 884.8M | ||||||
| Avg | 780.4M | 841.7M | ||||||
| Low | 743.8M | 783.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.2% | 13.4% | ||||||
| Avg | 7.4% | 7.9% | ||||||
| Low | 2.4% | 0.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 3.13 | 4.21 | |||||
| Avg | 2.93 | 3.67 | |||||
| Low | 2.68 | 3.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 1,882.5% | 44.0% | |||||
| Avg | 1,753.5% | 25.5% | |||||
| Low | 1,600.1% | 6.5% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.